Biopath Holdings Inc. announced that the company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules). The new technology, being licensed in the field of neutral lipid-based liposome delivery of antisense technologies and FAK siRNA, will enhance the company's liposome delivery technology by adding vectors to the liposomes targeted to a receptor that is specifically over-expressed on a majority of solid and hematological tumors and on 80% of metastatic epithelial tumors. The new liposome tumor targeting technology being licensed will be developed as an extension of the Company's current delivery technology, with a goal toward more powerfully focusing delivery of the antisense and FAK siRNA cancer treatments to the tumor tissue. Adding a vector to the liposome that targets a receptor that is highly expressed on the surface of tumor cells is expected to drive uptake of the liposomes into the tumor tissue, enhancing relative deposition in the target tumor tissue. In animal studies conducted at M. D. Anderson Cancer Center, researchers demonstrated an ability for vector targeted neutral lipid-based liposomes to increase transfection efficiency and siRNA molecule uptake fivefold to eightfold into cancer cells compared to those of untargeted liposomes and controls. These efficiencies are in addition to the delivery efficiencies noted above from the core neutral lipid-based liposome delivery technology.

On 08/11/2009, Biopath Holdings, Inc announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Biopath Holdings Inc. provided an update of drug development operations and also discussed a new liposome tumor targeting technology that it plans to develop. Bio-Path is currently developing a neutral lipid-based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules). Antisense and siRNA drugs are targeted to block the expression of specific disease-causing proteins while having little or no effect on other healthy tissue. Development of antisense and siRNA, however, has been limited by the lack of a suitable method to deliver these drugs to the diseased cells with high uptake into the cell without causing toxicity. Bio-Path's currently licensed neutral lipid-based liposome technology was developed to accomplish this, and studies have shown a significant increase in tumor cell uptake with this technology compared to other delivery methods. The company's operations to date have focused on initiating a Phase I clinical trial for its lead cancer drug candidate, which potentially could demonstrate that the delivery technology is performing as expected. The company is currently in the process of licensing new tumor targeting technology that represents next-generation development of its liposome delivery technology. The new technology being licensed will enhance the company's liposome delivery technology by adding vectors to the liposomes targeted to a receptor that is specifically over-expressed on a majority of solid and hematological tumors and on a reported 80% of metastatic epithelial tumors. The Company believes this tumor-targeting technology for antisense and siRNA delivery represents a highly promising strategy for treating primary and metastatic cancers. The new tumor targeting technology being licensed will be developed as an extension of the company's current delivery technology, with a goal toward more powerfully focusing delivery of the antisense and siRNA cancer treatments to the tumor tissue. Adding a vector to the liposome that targets a receptor that is highly expressed on the surface of tumor cells is expected to drive uptake of the liposomes into the tumor tissue enhancing relative deposition in the target tumor tissue.